Loading
A phase 3 trial of Apalutamide in prostate cancer, run by Janssen Pharmaceutica N.V., Belgium, active and no longer recruiting.
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer is a phase 3 interventional study registered as NCT04557059 by Janssen Pharmaceutica N.V., Belgium, with 691 participants enrolled, started 2020-11-12 and due to reach its primary completion in 2029-08-27. Interventions recorded: Radiotherapy, LHRHa and Apalutamide.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Apalutamide, Localised prostate cancer, high and very high risk, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson and the tag pipeline.
Shares Apalutamide, Localised prostate cancer, high and very high risk, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson and the tag pipeline.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson and the tag pipeline.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Androgen deprivation & AR pathway inhibitors, Prostate cancer and the tag pipeline.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Localised prostate cancer, high and very high risk, Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/